drugset / Trial / NCT03235219

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

NCT03235219

Phase 1 Completed 39 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this Phase 1b study is to assess the safety and tolerability of JNJ-64565111 in adult men and women (of non-child bearing potential) with Type 2 Diabetes Mellitus.

Timeline

Start
2017-08-01
Primary completion
2018-02-19
Completion
2018-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown Subcutaneous